Keywords: Optimer Pharma, Astellas, Dificlir, European launch, Milestone
Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe
Article | 11 June 2012
USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5 million) in milestone payments from partner ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
